These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1071971)

  • 41. Role of prostaglandin in the depressed cell-mediated immune response in rheumatoid arthritis.
    Wolinsky SI; Goodwin JS; Messner RP; Williams RC
    Clin Immunol Immunopathol; 1980 Sep; 17(1):31-7. PubMed ID: 6447561
    [No Abstract]   [Full Text] [Related]  

  • 42. Regulation of human B cell proliferation by prostaglandin E2.
    Thompson PA; Jelinek DF; Lipsky PE
    J Immunol; 1984 Nov; 133(5):2446-53. PubMed ID: 6332851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunosuppression associated with SJL/J murine lymphoma. I. Suppression of cell-mediated immune responses after tumor transplantation.
    Kumar RK; Lykke AW; Penny R
    J Natl Cancer Inst; 1981 Dec; 67(6):1269-75. PubMed ID: 6458725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune dysfunction in diabetes-prone BB rats. Interleukin 2 production and other mitogen-induced responses are suppressed by activated macrophages.
    Prud'homme GJ; Fuks A; Colle E; Seemayer TA; Guttmann RD
    J Exp Med; 1984 Feb; 159(2):463-78. PubMed ID: 6607315
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulation of human B cell activation by prostaglandin E2. Suppression of the generation of immunoglobulin-secreting cells.
    Jelinek DF; Thompson PA; Lipsky PE
    J Clin Invest; 1985 Apr; 75(4):1339-49. PubMed ID: 3872889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. LY-2+ effectors cytotoxic for syngeneic tumor cells: generation by allogeneic stimulation and by supernatants from mixed leukocyte cultures.
    Hurrell SM; Zarling JM
    J Immunol; 1983 Aug; 131(2):1017-23. PubMed ID: 6223084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro induction of tumor-specific immunity. II. Activation of cytotoxic lymphocytes to murine oncofetal antigens.
    Chism SE; Burton RC; Warner NL
    J Natl Cancer Inst; 1976 Aug; 57(2):377-87. PubMed ID: 63560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts.
    Fujimoto S; Greene MI; Sehon AH
    J Immunol; 1976 Mar; 116(3):791-9. PubMed ID: 1082894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune regulation of the L5178Y murine tumor-dormant state. I. In vivo and in vitro effects of prostaglandin E2 and indomethacin on tumor cell growth.
    Liu CM; Okayasu T; Goldman P; Suzuki Y; Suzuki K; Wheelock EF
    J Exp Med; 1986 Oct; 164(4):1259-73. PubMed ID: 3489807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secondary cytotoxic tumor immune response induced in vitro.
    Röllinghoff M
    J Immunol; 1974 May; 112(5):1718-25. PubMed ID: 4544796
    [No Abstract]   [Full Text] [Related]  

  • 51. Host reactivity against clonable tumor cells and the total tumor cell population, studied in a syngeneic murine lymphoma system.
    Gjedde SB
    Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):101-8. PubMed ID: 6349250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regulation of the immune response to tumor antigens. III. Characterization of thymic suppressor factor(s) produced by tumor-bearing hosts.
    Greene MI; Fujimoto S; Sehon AH
    J Immunol; 1977 Aug; 119(2):757-64. PubMed ID: 69667
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibitory effect of tumor-bearing state on the generation of in vivo protective immune T cells in a syngeneic murine tumor system.
    Fujiwara H; Hamaoka T; Nishino Y; Kitagawa M
    Gan; 1977 Oct; 68(5):589-601. PubMed ID: 73490
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition by lymphoid cellular factors of the immunological cytotoxicity against a syngeneic tumour.
    Lafontaine N; Firket H
    Pathol Eur; 1976; 11(2):147-50. PubMed ID: 958732
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hydrocortisone and inhibitors of prostaglandin synthesis. Potentiation of allograft survival in mice.
    Belldegrün A; Cohen IR; Frenkel A; Servadio C; Zor U
    Transplantation; 1981 Jun; 31(6):407-8. PubMed ID: 7020178
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulation of the immune response by prostaglandins.
    Goodwin JS; Webb DR
    Clin Immunol Immunopathol; 1980 Jan; 15(1):106-22. PubMed ID: 6987016
    [No Abstract]   [Full Text] [Related]  

  • 58. Analysis of the mechanism of allograft rejection and cell-mediated immunity. I. Accelerated rejection of tumour allografts without augmented cytotoxicity in the spleen cells.
    Nanishi F; Nomoto K; Taniguchi K; Kubo C
    Immunology; 1980 May; 40(1):67-76. PubMed ID: 7419243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective thymus-derived cell enrichment in the rat spleen as a result of immunodepression by urethan.
    Di Marco AT; Franceschi C; Prodi G
    Cancer Res; 1972 Jul; 32(7):1569-73. PubMed ID: 4402277
    [No Abstract]   [Full Text] [Related]  

  • 60. [Immunosuppressive phenomena in experimental tumor systems (author's transl)].
    Reme TX
    Pathol Biol (Paris); 1977 Dec; 25(10):735-40. PubMed ID: 349487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.